Understand the source comparison
Belly Fat Peptides 2026 Update: Comparison Table
Survodutide Dual GLP-1/GIP receptor agonist 18.3% (4.8mg weekly) 6.8 days Subcutaneous Phase 2 complete, Phase 3 enrolling Mazdutide Dual GLP-1/glucagon receptor agonist 17.1% (6mg weekly) 5.2 days Phase 3 complete, regulatory review CJC-1295/Ipamorelin AMPK a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide
- Dual GLP-1/GIP receptor agonist
- 18.3% (4.8mg weekly)
- 6.8 days
- Subcutaneous
- Phase 2 complete, Phase 3 enrolling
- Mazdutide
- Dual GLP-1/glucagon receptor agonist
- 17.1% (6mg weekly)
- 5.2 days
- Phase 3 complete, regulatory review
- CJC-1295/Ipamorelin
- AMPK activation + GHSR-1a agonism
- 11.4% (combined 5mg/5mg weekly)
- 8+ days (CJC), 2 hours (Ipamorelin)
- Mechanistic clarity published Q1 2026
- Semaglutide
- GLP-1 receptor agonist
- 10.7% (2.4mg weekly)
- 7 days
- Established baseline for comparison
- Tesofensine
- Monoamine reuptake inhibitor
- 9.2% (0.5mg daily)
- 8 days
- Oral
- Phase 3 stalled, limited 2026 data
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist
- 6.8% (25mg daily)
- 24 hours
- Oral bioavailability confirmed, visceral fat data weak